Nulojix (Belatacept)

Phase 2

BRISTOL MYERS SQUIBB CO (CELG-RI)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Renal Transplant

View Full Landscape

Drug Information

Target Indication

Renal Transplant

Clinical Trial

NCT02738918

Last updated: 9/5/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/17/2011

Nulojix

Nulojix, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

CELG-RI

BRISTOL MYERS SQUIBB CO

Biotechnology•North America•NASDAQ

Related Pipeline

MavacamtenPhase 3

Cardiomyopathy, Hypertrophic

AbataceptPhase 3

Rheumatoid Arthritis

Atazanavir/RitonavirPhase 3

HIV

StavudinePhase 3

HIV Infections

EntecavirPhase 3

Hepatitis B, Chronic

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts